Member Info for crumbs

I was just surprised it took him so long to appear must have a new hobby... anyways seem he got flushed early

It was noughty :)

This hold up is not directly down to BOD or scancell however they ought to have been aware Inovio had issues with the FDA in getting their latest device trial approved they got provided the wanted further paper work and got it approved... JC lives right near Ichor surely the relationships is good enough that they both worked to make sure the FDA had ALL relevant information required in time to get the trial going!!!... surely good planning is all about planning for such events as these.... plenty of pi could see this potentially happening!.....anyways market reaction is ridiculous and a buying op as like inovio I doubt there will be any problems in getting the Ichor device approved for trial the old version has been in trial and the new one already is in Europe....

A phenomenon we have witnessed for a long time and one that has concerned our ii so much they have attempted to be proactive against it .... think of most recent calculus event and Hygea have tried too... what can be done?

Well if you can make a recording and share it there will be many thankful non atendees ... but if not any reporting back you can share here will do cheers... how many sweat drops on Cliffs brow for instance lol

It's a valuable mission for all of us who are unable to attend so pre-thanks to anyone able to do that for us... seems this one will be a very important AGM... CH and FC may as well say nothing but have sorry about the sp faces on and leave it all to LD and SA :)

The ouch's posts are gone! poof

Will anyone record AGM this year?.... want to hear the seat squirms :)

Not necessarily .. maybe moditope is the TCR key to success?... get them T Cells to target cancer

Not looking good for them sadly... but hey least they managed to seduce GSK and get $500 million off them we have a successful trial and no deals and an sp that sinks worse on a non fatal FDA delay than fatalities in a trial!!! The world seems upside down mad

We are not Adaptimmune... however their mcap still dwarfs ours despite them getting a right market kicking on this data.... yup you would never ever know scancell has a beyond expectation successful trial already under its belt with a product that works in SCIB1 all I can think is it is all due to fashion CI's are in and cell therapies are all it.... anyways on data like this people are going to have to look elsewhere for solutions...

'Adaptimmune Therapeutics plc (NASDAQ:ADAP) fell $3.21 (30%) to $7.55 on Monday after reporting that zero of 17 evaluable patients achieved a response across the first two dose cohorts of three Phase I trials evaluating the company's MAGE-A10 and MAGE-A4 SPEAR T cell therapies to treat various cancers. Data were presented at the European Society for Medical Oncology meeting in Munich.

Among 11 evaluable patients with non-small cell lung cancer (NSCLC), melanoma or head and neck cancer in two Phase I trials of MAGE-A10, eight patients had disease progression, one patient died of pneumonia unrelated to treatment, one patient had stable disease at week four but then progressed, and one patient had stable disease at weeks four and eight but progressed at week 12. Seven patients had serious adverse events, including two with cytokine release syndrome (CRS) and one with hemoptysis.

Among six evaluable patients with ovarian cancer in a Phase I basket trial of MAGE-A4, there were four cases of stable disease and two cases of disease progression. Four patients had serious adverse events, including one with treatment-related muscular weakness and one with treatment-related CRS and encephalopathy.

MAGE-A10 comprises T cells modified to express TCRs targeting melanoma-associated antigen A10 (MAGEA10) and MAGE-A4 comprises T cells modified to express TCRs targeting MAGEA4.

Adaptimmune said all three trials have advanced to their respective third dose cohorts. The company added that the benefit of its T cell therapies may become evident at higher cell doses where it expects to see higher T cell expansion.'

At least there shouldn't be a cash call to finish off trials too soon now lol.. and we have been told a deal could be done on modi soon as it shows itself effective in trial so might mean we are better throwing most resources at that now... still plenty coming here.. GC results in January and we can expect more from BioNtech as in a deal... they are already listed as a partner on the scancell website...

At this rate, it may well be that the modi1 trial is our next one seeing as that one relies only on scancell and the adjuvant supplier who we have a deal in place with and we are told manufacture is underway already and will be done in the UK so let us hope that is all systems go early next year...

Well, what we do know is whatever nano tech was used in mouse models already not only worked it worked better than any previous delivery techs...I'd have hoped we would have done a deal on the tech we will use by now... it's just another hold up

My answer would be yes...Think the nano delivery requires some chemical combination

Can't but agree with him... trouble is it's complete silence on nano delivery ever since it was brought to our attention no deal done with a third party there yet-why?... it must be a hurdle in the way for the SCIB2 combo and CRUK getting the trial running, we don't want that one slipping into sometime 2020... should be another question for BOD that...

Stop losses maybe?

I remember Inovio had some FDA problems over their device and an upcoming trial... it all got sorted in the end but gave their sp a bashing at the time too

The new Ichor is a device ready for commercialisation meaning if SCIB1 were to go commercial it would need that device...... though we are still waiting to hear about the new nano delivery approach for SCIBs which one day could mean we can move away from electroporation devices for good....at the moment though for SCIB1 at least we are stuck with this electro approach and Ichor

TF I agree having KF etc not being involved would be horrible but might end up being practical ... SCIB1 is still scancells most valuable asset as it is already trial proven though from mcap you would never believe it!

Of course, the market always does this-nothing to do with mm, of course, lol... all patients on an arm of a trial alive after 5 benchmark years no %rise new platform arrives no %rise a non-fatal delay due to a third-party device... burn the world down! lol... yes a good buying op I expect AGM to be full of positives and this to get back up over 10p...